PMID- 32783766
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 2164-554X (Electronic)
IS  - 2164-5515 (Print)
IS  - 2164-5515 (Linking)
VI  - 16
IP  - 9
DP  - 2020 Sep 1
TI  - Immune-engineered H7N9 influenza hemagglutinin improves protection against viral 
      influenza virus challenge.
PG  - 2042-2050
LID - 10.1080/21645515.2020.1793711 [doi]
AB  - The influenza hemagglutinin (HA) isolated from avian H7N9 influenza virus strains 
      elicit weak immune responses. This low immunogenicity may be due to a regulatory 
      T cell (T(reg))-stimulating epitopes in HA from the H7N9 isolate A/Anhui/1/2013 
      (Anh/13). In this report, this T(reg) stimulating sequence was removed from the 
      wild-type (WT) H7 HA amino acid sequence and replaced with a conserved CD4 + T 
      cell stimulating sequences from human seasonal H3N2 strains and designed OPT1 H7 
      HA. The effectiveness of this optimized H7 HA protein was determined using a 
      humanized mouse (HLA-DR3) expressing the human leukocyte antigen (HLA) DR3 
      allele. HLA-DR3 mice were pre-immunized by infecting with H3N2 influenza virus, 
      A/Hong Kong/4108/2014 and then vaccinated intramuscularly with either the WT 
      H7 HA from Anh/13 or the OPT1 H7 HA antigen without adjuvant. The OPT1 H7 HA 
      vaccination group elicited higher H7 HA-specific IgG titers that resulted in a 
      lower mortality, weight loss, and lung viral titer following lethal challenge 
      with the H7N9 Anh/13 influenza virus compared to WT-vaccinated mice. Overall, 
      T-cell epitope-engineered vaccines can improve the immunogenicity of H7 HA 
      antigens resulting in enhanced survival and lower morbidity against H7N9 
      influenza virus challenge.
FAU - Jang, Hyesun
AU  - Jang H
AD  - Department of Infectious Diseases, University of Georgia , Athens, GA, USA.
AD  - Center for Vaccines and Immunology, University of Georgia , Athens, GA, USA.
FAU - Meyers, Lauren M
AU  - Meyers LM
AD  - EpiVax , Providence, RI, USA.
FAU - Boyle, Christine
AU  - Boyle C
AD  - EpiVax , Providence, RI, USA.
FAU - De Groot, Anne S
AU  - De Groot AS
AD  - Center for Vaccines and Immunology, University of Georgia , Athens, GA, USA.
AD  - EpiVax , Providence, RI, USA.
FAU - Moise, Lenny
AU  - Moise L
AD  - EpiVax , Providence, RI, USA.
AD  - Institute of Immunology and Informatics, Department of Cell and Molecular 
      Biology, University of Rhode Island , Providence, RI, USA.
FAU - Ross, Ted M
AU  - Ross TM
AD  - Department of Infectious Diseases, University of Georgia , Athens, GA, USA.
AD  - Center for Vaccines and Immunology, University of Georgia , Athens, GA, USA.
LA  - eng
GR  - R01 AI132205/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200812
PL  - United States
TA  - Hum Vaccin Immunother
JT  - Human vaccines & immunotherapeutics
JID - 101572652
RN  - 0 (Antibodies, Viral)
RN  - 0 (Hemagglutinin Glycoproteins, Influenza Virus)
RN  - 0 (Hemagglutinins)
RN  - 0 (Influenza Vaccines)
SB  - IM
MH  - Animals
MH  - Antibodies, Viral
MH  - Hemagglutinin Glycoproteins, Influenza Virus/genetics
MH  - Hemagglutinins
MH  - Influenza A Virus, H3N2 Subtype
MH  - *Influenza A Virus, H7N9 Subtype/genetics
MH  - *Influenza Vaccines
MH  - *Influenza, Human/prevention & control
MH  - Mice
MH  - *Orthomyxoviridae Infections/prevention & control
PMC - PMC7553694
OTO - NOTNLM
OT  - Asian H7N9
OT  - T cell epitope engineering
OT  - humanized mouse model
OT  - pandemic influenza vaccine
EDAT- 2020/08/14 06:00
MHDA- 2021/06/22 06:00
PMCR- 2020/08/12
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/12 00:00 [pmc-release]
AID - 1793711 [pii]
AID - 10.1080/21645515.2020.1793711 [doi]
PST - ppublish
SO  - Hum Vaccin Immunother. 2020 Sep 1;16(9):2042-2050. doi: 
      10.1080/21645515.2020.1793711. Epub 2020 Aug 12.